ArticlebioRxiv : the preprint server for biology2024

A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind.

Rena Emond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.